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The adipokine resistin is an insulin-antagonizing factor that also plays a regulatory role in inflammation, immunity, food intake,
and gonadal function and also regulates growth hormone (GH) secretion in rat adenopituitary cells cultures with the adipokine.
Although adipose tissue is the primary source of resistin, it is also expressed in other tissues, including the pituitary. The aim
of this study is to investigate the possible action of resistin on the lipid metabolism in the pituitary gland in vivo (rats in two
different nutritional status, fed and fast, treated with resistin on acute and a chronic way) and in vitro (adenopituitary cell cultures
treated with the adipokine). Here, by a combination of in vivo and in vitro experimental models, we demonstrated that central acute
and chronic administration of resistin enhance mRNA levels of the lipid metabolic enzymes which participated on lipolysis and
moreover inhibiting mRNA levels of the lipid metabolic enzymes involved in lipogenesis. Taken together, our results demonstrate
for the first time that resistin has a regulatory role on lipid metabolism in the pituitary gland providing a novel insight in relation
to the mechanism by which this adipokine can participate in the integrated control of lipid metabolism.
1. Introduction
Resistin, also known as found in inflammatory zone 3
(FIZZ3) is an adipocyte-derived hormone known to promote
insulin resistance, impair adipocyte differentiation, and to
promote inflammation [1–5] and that was originally identi-
fied in rats as a protein secreted by adipocytes that is under
the control of different humoral signals and nutritional status;
nutrition and metabolism regulate this adipoine. Resistin
is decreased in fasting situations [6], whereas circulating
resistin is increased in obese insulin resistant rodents [7]
and humans [8]. Despite adipose tissue being the more
relevant source of this protein, it has been recently reported
that resistin is also expressed in the hypothalamus and in
the pituitary gland [8, 9]. Central resistin administration
appears to have a dual effect on metabolic homeostasis, first
by acutely inhibiting feeding [10] and second by controlling
glucose homeostasis and inducing hepatic insulin resistance
[8, 11]. Recently, it has been demonstrated that central resistin
regulates hypothalamic and peripheral lipid metabolism in a
nutritional-dependent fashion and even that this regulation
is opposite in peripheral organs in comparison with central
effect [12]. The authors demonstrate that the anorectic effect
of resistin is associated with the low levels of mRNA expres-
sion of orexigenic (agouti-related protein and neuropeptide
Y) and the increased mRNA expression of anorexigenic
(cocaine and amphetamine-regulated transcript) neuropep-
tides in the arcuate nucleus of the hypothalamus. Also
they show that resistin exerts a nutritional status dependent
inhibitory effect on hypothalamic fatty acid metabolism,
as indicated by increased phosphorylation levels of both
AMP-activated protein kinase and its downstream target
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acetyl-coenzyme A carboxylase, associated with decreased
expression of fatty acid synthase in the hypothalamus. In
addition, it is demonstrated that chronic central resistin
infusion results in decreased body weight and major changes
in peripheral expression of lipogenic enzymes, in a tissue-
specific and nutrition-dependent manner [12].
In previous studies we tested the resistin effect on GH
release in vitro. It has been demonstrated that the adipoine
induces GH release in a dose fashion on adenopituitary cells
culture at 4 h of exposition.This effect is even higher at 24 h of
resistin treatment [13].These results implicate the existence of
resistin receptors in the pituitary, a receptor which it has not
been cloned yet.
The aim of this study was to characterize the effect of
acute and chronic resistin administration in the regulation of
pituitary lipid metabolism. In addition since this adipokine
have been reported to be involved in the inflammation
process linked to obesity, we also studied its effects on the
expression of the most-known proinflammatory cytokines,
namely, TNF-alpha and Il-6 [14].
We have studied the expression of enzymes; fatty acid
synthase, FAS; malonyl CoA decarboxylase, MCD; carnitina-
palmitoil transferase, CPT-1; lipoprotein lipase, LPL; the
proinflammatory cytokines interleukin 6, IL-6; tumor necro-
sis factor alfa, TNF-𝛼.
2. Materials and Methods
2.1. Reagents. The fetal bovine serum (FBS) was obtained
from Fisher Scientific Biobloce. Trizol reagent and MML-V
reverse transcriptase (RT) were purchased from Invitrogen
(Paisley, UK). Dulbecco’smodified Eagle’smedium (DMEM),
collagenase from Clostridium histolyticum, deoxiribonucle-
ase I crude lyophilized, hyaluronidase type I-S from Bovine
test, Dispase II (neutral protease, grade II) from Roche
Diagnostics, SL. (Barcelona, Spain). Resistin was obtained
from Phoenix Pharmaceuticals Inc. (Karlsruhe, Germany);
10 𝜇g/rat dissolved in 5𝜇L of saline.
2.2. Animals. Male Sprague Dawley rats (300–350 g) were
housed in a temperature-controlled room, with a 12-h light,
12-h dark cycle (lights from 0800 to 2000 h).The experiments
were performed in agreement with the International Law
on Animal Experimentation, and the experimental protocols
have been approved by the Ethics Committee of the Uni-
versity of Santiago de Compostela. Intracerebroventricular
(ICV) cannulae chronic ICV cannulae were implanted under
ketamine/xylazine anesthesia as previously described [11, 15,
16].
The correct location of the cannula in the lateral ventricle
was confirmed by methylene blue staining. Animals were
individually caged and allowed to recover for 1 wk before
experiment. During the postoperative recovery period, the
rats were handled regularly under nonstressful conditions.
2.3. Acute Resistin Treatment. One group of rats was fed
ad libitum, and the other group was deprived of food for
12 h (nocturnal fasting). Rats then received either a single
ICV injection of resistin (Phoenix Pharmaceuticals Inc.,
Karlsruhe, Germany; 10𝜇g/rat dissolved in 5𝜇L of saline) or
vehicle. The rats were killed 1.5 h after injection. Treatments
started at 0800 h and were carried out in the light phase.
2.4. Chronic Resistin Treatment. Brain infusion cannulae
were stereotaxically placed into the lateral ventricle as
described above. A catheter tube was connected from the
brain infusion cannula to an osmotic minipump flow mod-
erator (model 2001D or 2ML2; Alza Corp., Palo Alto, CA,
USA). An sc pocket on the dorsal surface of the animal was
created using blunt dissection, and the osmotic minipump
was inserted. The incision was closed with sutures, and the
rats were kept warm until fully recovered. The rats were then
infused with either vehicle or resistin (10𝜇g/day) for 6 d. On
day 4, one group of rats was fed ad libitum, and the other
group was deprived of food for the final two days.
2.5. Pituitary Cell Dispersion and Culture. Isolated cells from
rat anterior pituitary were obtained using an enzymatic
dispersion protocol. Briefly, for each experiment, three to four
anterior pituitaries were pooled, minced, and enzymatically
dissociated by incubation in DMEM supplemented with col-
lagenase 0.4%, deoxyribonuclease 0.01%, hyaluronidase 0.1%,
and dispase II 0.2% at 37∘C in a 5% CO
2
atmosphere, and the
tissues were mechanically dispersed every 10 minutes until
a homogeneous cellular suspension was obtained. Cellular
viability, as estimated by the trypan blue test, was always
above 90%.
Dispersed anterior pituitary cells were plated at a density
of 300,000 cells onto 24-well culture plates in 1mL DMEM
supplemented with 10% FBS and 0.1% antibiotic-antimycotic
solution.
Cells were incubated at 37∘C in a 5% CO
2
atmosphere,
and medium was replaced by fresh DMEM-FBS after 48 h of
culture. After a 3-d culture period,mediumwas removed, and
cells were preincubated in 1mL serum-free DMEM for 2 h to
stabilize basal hormone secretion.Mediumwas then replaced
with fresh DMEM containing increasing doses of resistin or
the corresponding control vehicle and incubated for 4 h at
37∘C.
Medium samples were collected at the end of the exper-
iments and were stored at –20∘C until hormone determina-
tions by RIA.
Cells in the culture plates were processed for RNA
extraction as indicated below.
2.6. Measurement of Growth Hormone by RIA. GH levels in
culture media were measured in a volume of 25–50𝜇L
using a double antibody method and radioimmunoassay
kits kindly supplied by the NIH (Dr. A. F. Parlow, NIDDK
National Hormone and Peptide Program; Torrance, CA,
USA). RatGH-I-7was labeledwith 125I using the chloramine-
Tmethod and Iodo-Gen Pre-coated iodination tubes (Pierce,
Rockford, IL, USA), respectively. Hormone concentration
was expressed using the reference preparations GH-RP-2 as
standards. Intra- and interassay coefficients of variation were
below 6% and 9% for GH. The sensitivity of the assay was
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5 pg/tube for GH. Accuracy of hormone determinations was
confirmed by assessment of rat serum samples of known
hormone concentrations used as external controls.
2.7. Real-Time Quantitative PCR of Enzymes Involved in
Lipid Metabolism. The mRNA levels of acetyl-coenzyme A
carboxylase (ACC)𝛼, IL-6, TNF 𝛼, and lipoprotein lipase
(LPL) were studied by using real-time PCR (TaqMan;
Applied Biosystems, Foster City, CA, USA) by using spe-
cific primers and probes published as supplemental data
on The Endocrine society’s journals Online web site at
http://endo.endojournals.org/) as previously described [17,
18]. All reactions were carried out using the following cycling
parameters: 50∘C for 2min, 95∘C for 10min followed by 40
cycles of 95∘C for 15 sec, and 60∘C for 1min [17, 18].
For the analysis of the data, the input value of the gene
of interest was standardized to the 18S value for the sample
group andwas expressed comparedwith the average value for
the vehicle-treated group.We used six to eight rats per group.
2.8. Statistical Analysis. Data are expressed as mean ± SEM
in relation (%) to vehicle-treated rats. Statistical significance
was determined by 𝑡-Student’s test when two groups were
compared or by ANOVA and post-hoc two-tailed Bonferroni
test when more than two groups were compared. 𝑃 < 0.05
was considered significant.The program used for the analysis
was GraphPad Prism.
3. Results
3.1. Central Acute Administration of Resistin Does Not Regu-
late Pituitary Fatty Acid Metabolism. Central acute resistin
administration induced no changes in the mRNA expres-
sion of FAS, MCD, CPT-1, LPL, and the proinflammatory
cytokines IL-6 and TNF-𝛼 suggesting that pituitary gland
fatty acidmetabolism is not regulated by central acute resistin
treatment (Figure 1).
3.2. Central Chronic Administration of Resistin Regulates Pitu-
itary Fatty Acid Metabolism. Central chronic administration
of resistin was associated with a marked decreased in the
expression levels of FAS and LPL indicating that resistin
does not participate on lipid synthesis. We also observed
that CPT-1 and MCD mRNA levels are higher than in
fasting conditions and in presence of resistin. With respect to
the proinflammatory cytokines, resistin diminished mRNA
levels of both IL-6 and TNF-𝛼 on fasted rats (Figure 2).
3.3. Effect of Resistin on Rat Pituitary Cell Cultures. For know-
ing if resistin has a direct participation on pituitary lipid
metabolism, we have examined the effect of increasing doses
of resistin (10−14–10−6M) on mRNA levels by rat anterior
pituitary cell cultures exposed to the adipokine for 4 h. As
shown in Figure 3, when resistin is administered for 4 h,
significantly decreased FAS shows low levels of mRNA with
10−8M and 10−6M resistin concentrations. The LPL shows
decreased levels of the enzyme expression at the highest
resistin doses employed. With respect to CPT-1 enzyme,
resistin induces an enhanced transferase enzyme expression
at 10−8 and 10−6Mdoses of the adipokine.The two proinflam-
matory cytokines that we have studied showed low levels of
the mRNA at 10−6M. TNF-alpha even presents low levels at
other resistin concentrations (10−10M to 10−6M).
4. Discussion
Although resistin was initially suggested to promote insulin
resistance and adipocyte differentiation, recent data indicate
that this hormone also plays a pleiotropic role in rodents,
immunity, food intake, gonadal function, and hypothalamic
and peripheral lipid metabolism regulation [19]. A recent
study of our group added a new role to resistin, regulating
pituitary somatotrope cell function. Resistin enhances GH
release through the activation of multiple signaling pathways
[13].
Specifically, resistin enhanced GH release on ad libitum
feeding rats when resistin was administered in an acute (1.5 h)
or a chronic (6 d) way increasing the transcripts numbers
of the pituitary transcription factor Pit-1. It is important
to confirm whether resistin-induced changes in mRNA
expression of Pit-1 correlate with hormone protein levels,
because it has been recently reported that POMC altered
gene expression is not always linked to specific changes in 𝛼-
MSHhypothalamic protein content [20]. Further work, using
different experimental techniques as HPLC combined with
RIAor proteomic analysis, will help to clarify these issues [21].
Previous work in our group reported that 4 h of resistin
administration to dispersed rat anterior pituitary cells
increased GH release [13]. Therefore, our results confirm
the regulatory role of resistin on GH secretion with rats fed
ad libitum. It is widely accepted that the regulation of the
secretion of GH from the anterior pituitary gland is under
the reciprocal control of two hypothalamic hormones, the
stimulatory GHRH found in the arcuate nucleus and the
inhibitory hormone, somatostatin (SRIF), synthesized in the
periventricular nucleus [22]. Our results suggest that resistin
might regulateGHRHor SRIF secretion to obtainGH release,
or as it has been reported previously, resistin could act directly
over somatotropes to regulate GH release [13].
That resistin regulates lipid metabolism centrally and in
the periphery as has been reported by Kjems and coworkers
[12]. Herein, we have expanded the research to the pituitary
gland, studying if resistin regulates fatty acid metabolism in
the gland in vivo and in adenopituitary cells cultures in vitro.
We demonstrate that chronic central resistin administra-
tion during 6 d but, no acute administration during 90min,
modified the mRNA levels of the fatty acid metabolism
enzymes in the pituitary gland. Besides, resistin diminished
the IL-6 and TNF-𝛼 mRNA levels on the rat with resistin
chronic treatment and on the rat adenopituitary cultures
exposed to the adipokine. In detail, resistin diminished
mRNA levels of FAS in the pituitary gland and enhanced
mRNA levels of CPT-1 and MCD when resistin was admin-
istered during 6 d to rats, but there was no effect when the
adipokine was administered in an acute way (90min). Our
data showed that central chronic resistin treatment causes
a reduction in the number of transcripts of fat-promoting
























































































































































Figure 1: Effect of central acute administration of resistin on pituitary lipid metabolism enzymes and proinflammatory cytokines. Mean +
SEM mRNA levels of FAS, MCD, CPT-1, LPL, IL-6, and TNF-alpha in the pituitary gland of fed and fasted rats following administration
(I.C.V) of vehicle (Veh) or resistin (10 ug/rat). Samples were obtained 90min later.𝑁 = 6–8 rats per group assay.
enzymes in the gland and that the adipokine promotes to
𝛽-oxidation in a nutrition-independent fashion. The phys-
iological significance of this effect in the pituitary gland is
intriguing.We confirmed that fatty acidmetabolism enzymes
regulation in the gland is opposite to that described by other
authors in other peripheral tissues as white adipose tissue
and liver [12]. The reason why resistin increases CPT-1 and
MCD in pituitary and diminishes FAS expression is unclear;
however, it indicates that pituitary fatty acid metabolism
enzymes expressionmay be regulated bymechanisms distinct
from those operating in adipocytes and hepatocytes. Other
enzymes such as leptin also have different roles depending
on whether they act at the central or peripheral level [23]. On
the other hand, our results are similar in part with the results
of Kjems and coworkers published on the hypothalamus in
which central resistin diminished FAS mRNA levels [12].
We suggest that, as in the hypothalamus, low levels of
pituitary ACC mRNA may be a compensatory physiological
mechanism that prevents harmful high levels of malonyl-
CoA produced in the gland after FAS inhibition [24]. Respect
to CPT-1 and MCD, our results showed that CPT-1 mRNA
levels are enhanced in resistin-treated fed ratswithin the same
time frame, suggesting that malonyl-CoA levels are changed,
as a consequence of ACC inactivation and MCD activation
that maybe derived from the low ACC mRNA levels and the
high MCDmRNA levels.
Recent data point to the fact that central resistin induces
hepatic insulin resistance by increasing the expression of



























































































































































Figure 2: Effect of central chronic administration of resistin on pituitary lipid metabolism enzymes and proinflammatory cytokines. Mean
+ SEM mRNA levels of FAS, MCD, CPT-1, LPL, IL-6, and TNF-alpha in the pituitary gland of fed and fasted rats following administration
(I.C.V.) of vehicle (Veh) or resistin (10 ug/day/over six days. 𝑁 = 6–8 rats per group assay; ∗𝑃 < 0, 05 versus fed vehicle; #𝑃 < 0.05 versus
fasted vehicle.
proinflammatory cytokines, such as IL-6 and TNF𝛼, via an
unidentifiedmechanismmediated by the autonomic nervous
system [8, 11].Those alterations in proinflammatory adipocy-
tokines may be due, in part, to the excess accumulation
of fatty acids and triglycerides in the liver after central
treatment with resistin [25–27]. Therefore, the no increase
of fat deposition due to tilt toward the 𝛽-oxidation might at
least partially explain the low mRNA levels of IL-6 and TNF-
𝛼 on the gland after resistin treatment centrally and directly
on the adenopituitary cells cultures. Further investigation is
necessary to clarify this issue.
Finally, we investigated the effect of resistin on lipid
metabolism on pituitary cells cultures, and we found the
same result observed in vivo, resistin diminished the mRNA
levels of the enzymes involved in regulating triglyceride
uptake and lipid metabolism, such as LPL, ACC, FAS, SCD-1,
and key transcriptional factors regulating lipid metabolism,
such as SREBP-1c and enhanced the transcripts numbers
of CPT-1 and MCD when resistin was administered during
4 h on adenopituitary cells cultures. We found significant
activity at resistin 10−12 and resistin 10−10M, which is within
the concentration range of circulating resistin in rat [28].
Noteworthy, the effect of resistin did not follow a typical dose-
response pattern in receptor gene expression, an observation
that has been reported for this and other signallingmolecules
[29–32]. Although the reasons are unclear at present, several






























































































































































































































Figure 3: Effect of resistin on mRNA levels of lipid metabolism enzymes and proinflammatory cytokines in vitro. Mean + SEMmRNA levels
of ACC𝛼, CPT-1, FAS, LPL, MCD, SCD-1, SREBP, IL-6, and TNF-alpha. After 3 days of culture, dispersed rat pituitary cells were incubated
in medium alone (C, Control) or in the presence of resistin (10−14–10−6M) for 4 h. After culture, cells were harvested, and receptor mRNA
levels were determined by real-time RT-PCR. Enzymes band intensities were determined and adjusted by the signal intensity for HPRT. The
averaged results were then calculated and expressed as a percentage of vehicle-treated control levels (100%). Data are the mean (±SEM) of
three separate experiments. At least three replicate wells were evaluated per treatment in each experiment. ∗𝑃 < 0, 05 versus corresponding
control.
possibilities can be put forward. It is possible that, depending
on its concentration, resistin might induce different struc-
tural conformations of its receptor(s) and/or the selective
interaction of resistin receptor(s) with other receptors (i.e.,
homo- or heterodimerization), which in turn might modify
resistin activity as it has been reported to occur for other
receptors in response to their corresponding ligands [33].
Anyhow, it is yet unknown whether the effects of resistin are
mediated by one or several receptors because none has been
identified. If there is more than one receptor for resistin, it
could be possible that they may have different affinities for
resistin with different biological effects that could explain
the atypical dose-response curves observed herein. However,
until more data, these explanations are presently speculative.
Resistin could be inducing to 𝛽-oxidation against to promote
fat storage. Other peptides as ghrelin or GHRH being GH
secretagogues have a similar behaviour on lipid metabolism
in the pituitary (preliminary data from our laboratory).
Besides, resistin diminished the IL-6 and TNF-𝛼 mRNA
levels on rat adenopituitary cultures exposed to the adipokine
as occured in the in vivo experiments. These results show
that resistin promotes the 𝛽-oxidation in the pituitary gland,
decreasing the levels of proinflammatory cytokines and that
the adipokine does this action directly on anterior pituitary
cells, showing that the pituitary gland could be a target in the
control of diseases caused by insulin resistance.
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In summary we show that administration of resistin to
rats in vivo and to adenopituitary cell cultures in vitro evoked
important effects on pituitary.
Chronic infusion of central administration of resistin
increased enzymes mRNA levels implicated on lipid 𝛽-
oxidation activity and inhibited mRNA expression levels of
the enzymes involved on lipid synthesis in vivo and in vitro.
Chronic administration of the adipokine decreased IL-
6 and TNF-𝛼 transcripts numbers in vivo and on primary
cultures experiments.
When viewed together, these results provide evidence
that pituitary is a direct and indirect target of resistin action
for lipidmetabolism regulation of the gland itself. It is feasible
that pituitary adipokine expression serves as a link between
peripheral metabolic signals. Pituitary control fat storage
and metabolism could provide another important step in
unraveling the interactions between center, periphery, and
adipocytokines, which will improve our understanding of
metabolic syndrome and obesity.
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